Compare ROKU & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ROKU | ROIV |
|---|---|---|
| Founded | 2002 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Cable & Other Pay Television Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.9B | 14.1B |
| IPO Year | 2017 | N/A |
| Metric | ROKU | ROIV |
|---|---|---|
| Price | $110.58 | $22.87 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 19 | 8 |
| Target Price | ★ $115.05 | $21.94 |
| AVG Volume (30 Days) | 2.9M | ★ 6.7M |
| Earning Date | 10-30-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,543,395,000.00 | $20,329,000.00 |
| Revenue This Year | $16.44 | N/A |
| Revenue Next Year | $13.05 | $376.94 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 16.61 | N/A |
| 52 Week Low | $52.43 | $8.73 |
| 52 Week High | $116.66 | $22.45 |
| Indicator | ROKU | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 68.54 | 71.09 |
| Support Level | $91.66 | $20.14 |
| Resistance Level | $112.42 | $21.48 |
| Average True Range (ATR) | 4.32 | 0.77 |
| MACD | 1.57 | 0.09 |
| Stochastic Oscillator | 87.03 | 88.97 |
Roku enables consumers to stream television programming. It has more than 90 million streaming households and provided 127 billion streaming hours in 2024. Roku is the top streaming operating system in the US, reaching more than half of broadband households, according to the company. Roku's OS is built into streaming devices and televisions that Roku sells and on connected televisions from other manufacturers that license Roku's name and software. Roku also operates the Roku Channel, a free, ad-supported streaming television platform that offers a mix of on-demand and live television programming. Roku generates revenue primarily from selling devices, licensing, and advertising, and it receives fees from subscription streaming platforms that sell subscriptions through Roku.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.